Evidence map›Paper›PMID 30961169›Full record

ArticlePolymers2018

Cell Uptake and Biocompatibility of Nanoparticles Prepared from Poly(benzyl malate) (Co)polymers Obtained through Chemical and Enzymatic Polymerization in Human HepaRG Cells and Primary Macrophages.

Hubert Casajus, Saad Saba, Manuel Vlach, Elise Vène, Catherine Ribault, Sylvain Tranchimand, Caroline Nugier-Chauvin, Eric Dubreucq, Pascal Loyer, Sandrine Cammas-Marion and 1 more

Abstract read
In one paragraph

Article in Polymers, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Circumsporozoite Protein ofPharmaceutics · 2022
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Hubert CasajusEcole Nationale Supérieure de Chimie de Rennes, Univ Rennes, CNRS, ISCR, UMR 6226, F-35000 Rennes, France. casajus.hubert@gmail.com.ORCID 0000-0002-2560-181X
Saad SabaUniv Rennes, INSERM, INRA, Institut NUMECAN (Nutrition Metabolisms and Cancer) UMR_A 1341, UMR_S 1241, F-35000 Rennes, France. saad.saba@etudiant.univ-rennes1.fr.
Manuel VlachUniv Rennes, INSERM, INRA, Institut NUMECAN (Nutrition Metabolisms and Cancer) UMR_A 1341, UMR_S 1241, F-35000 Rennes, France. manuel.vlach@univ-rennes1.fr.
Elise VèneUniv Rennes, INSERM, INRA, Institut NUMECAN (Nutrition Metabolisms and Cancer) UMR_A 1341, UMR_S 1241, F-35000 Rennes, France. elise.vene@univ-rennes1.fr.
Catherine RibaultUniv Rennes, INSERM, INRA, Institut NUMECAN (Nutrition Metabolisms and Cancer) UMR_A 1341, UMR_S 1241, F-35000 Rennes, France. catherine.ribault@univ-rennes1.fr.
Sylvain TranchimandEcole Nationale Supérieure de Chimie de Rennes, Univ Rennes, CNRS, ISCR, UMR 6226, F-35000 Rennes, France. sylvain.tranchimand@ensc-rennes.fr.ORCID 0000-0001-6761-3758
Caroline Nugier-ChauvinEcole Nationale Supérieure de Chimie de Rennes, Univ Rennes, CNRS, ISCR, UMR 6226, F-35000 Rennes, France. caroline.nugier@ensc-rennes.fr.
Eric DubreucqMontpellier SupAgro, INRA, CIRAD, Univ Montpellier, UMR 1208 IATE, F-34060 Montpellier, France. eric.dubreucq@supagro.fr.ORCID 0000-0002-8904-504X
Pascal LoyerUniv Rennes, INSERM, INRA, Institut NUMECAN (Nutrition Metabolisms and Cancer) UMR_A 1341, UMR_S 1241, F-35000 Rennes, France. pascal.loyer@univ-rennes1.fr.
Sandrine Cammas-MarionEcole Nationale Supérieure de Chimie de Rennes, Univ Rennes, CNRS, ISCR, UMR 6226, F-35000 Rennes, France. sandrine.marion.1@ensc-rennes.fr.ORCID 0000-0001-6552-8082
Nicolas LepareurUniv Rennes, INSERM, INRA, Institut NUMECAN (Nutrition Metabolisms and Cancer) UMR_A 1341, UMR_S 1241, F-35000 Rennes, France. n.lepareur@rennes.unicancer.fr.ORCID 0000-0001-9860-5451

Funding

Centre National de la Recherche Scientifique N/AInstitut National de la Santé et de la Recherche Médicale N/Aislamic center association for guidance and higher education PhD grantLigue Contre le Cancer Comités 17 et 35Ministère de l'Education Nationale, de l'Enseignement Supérieur et de la Recherche PhD grant
6 · The paper itself

Abstract

The design of drug-loaded nanoparticles (NPs) appears to be a suitable strategy for the prolonged plasma concentration of therapeutic payloads, higher bioavailability, and the reduction of side effects compared with classical chemotherapies. In most cases, NPs are prepared from (co)polymers obtained through chemical polymerization. However, procedures have been developed to synthesize some polymers via enzymatic polymerization in the absence of chemical initiators. The aim of this work was to compare the acute in vitro cytotoxicities and cell uptake of NPs prepared from poly(benzyl malate) (PMLABe) synthesized by chemical and enzymatic polymerization. Herein, we report the synthesis and characterization of eight PMLABe-based polymers. Corresponding NPs were produced, their cytotoxicity was studied in hepatoma HepaRG cells, and their uptake by primary macrophages and HepaRG cells was measured. In vitro cell viability evidenced a mild toxicity of the NPs only at high concentrations/densities of NPs in culture media. These data did not evidence a higher biocompatibility of the NPs prepared from enzymatic polymerization, and further demonstrated that chemical polymerization and the nanoprecipitation procedure led to biocompatible PMLABe-based NPs. In contrast, NPs produced from enzymatically synthesized polymers were more efficiently internalized than NPs produced from chemically synthesized polymers. The efficient uptake, combined with low cytotoxicity, indicate that PMLABe-based NPs are suitable nanovectors for drug delivery, deserving further evaluation in vivo to target either hepatocytes or resident liver macrophages.

Indexed as

biocompatible nanoparticlescell uptakechemical polymerizationcytotoxicityenzymatic polymerizationHepaRG cellshuman macrophagespoly(benzyl malate)

Identifiers

PMID30961169
PMCPMC6401887

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.